GLP-1 Before Surgery: Anesthesia, Colonoscopy, and Sedation

Matthew Segar

Medically Reviewed

Matthew Segar, MD, MS

Cardiologist and Electrophysiology Fellow

Written by Jake Dickson, NASM-CPT, USAW-L2

Published: July 19, 2026 9 Min Read
Woman sitting on an exam table discussing a planned procedure with a healthcare provider.

Photo Credit: SDI Productions / iStock

Key Takeaways

  • Delayed gastric emptying from GLP-1s can leave your stomach fuller than standard fasting windows account for, which raises your aspiration risk during sedation.
  • Most patients can remain on their GLP-1 through elective surgery because newer guidance leans toward individual risk assessment rather than blanket hold periods.
  • When a pause is warranted, daily formulations usually stop the day of the procedure, while weekly injectables stop about a week out.
  • Nausea, reflux, or vomiting are not automatic dealbreakers, but they do raise your aspiration risk and shape your care team's decision.
  • Your dosing schedule, active symptoms, and personal risk profile determine the final plan, so you must share all three details with your care team.

One in eight Americans is using, or has used, a GLP-1. About one in nine people undergo surgery each year. When the numbers align this closely, it pays to be cautious.

Should you take your GLP-1 before surgery, a colonoscopy, or procedures that require sedation? At first, you might think the two have nothing to do with each other. But the American Society of Anesthesiologists (ASA) urges caution: "The potential benefit of withholding GLP-1s around surgery must be balanced against the risks."

Why? GLP-1s delay gastric emptying, which drastically impacts pre- and peri-surgery protocols. Here's what you need to know about GLP-1s before surgery.

How GLP-1s Affect Your Upcoming Procedure

GLP-1s directly affect your procedure because they delay gastric emptying and put an "ileal brake" on your digestive system. This brake slows the rate at which your body processes and passes food, meaning food remains in your stomach much longer than it otherwise would.

It's not a new phenomenon—scientists have discussed using this mechanism to control appetite for decades. Because food stays in the stomach longer, patients feel fuller longer, which reduces the compulsion to overeat. But while these effects work incredibly well for managing weight, having that partially digested food still sitting in your system is exactly what creates complications when it's time for anesthesia.

The Aspiration Risk: A Critical Safety Concern

Aspiration describes the movement of food, liquid, or other stomach contents into the lungs. Physical reflexes like coughing, gagging, or swallowing help you avoid aspiration, but are completely suppressed when you're anesthetized.

GLP-1 users carry a much higher risk of having retained stomach contents get into the lungs during sedation due to the drug's ability to slow gastric emptying. This is a life-threatening medical emergency. Pulmonary aspiration can cause severe chemical lung damage (aspiration pneumonitis), acute respiratory failure, and serious long-term complications.

Crucially, standard pre-surgery fasting windows (such as stopping solid foods 6 to 8 hours before a procedure) are often insufficient for GLP-1 users. Because the stomach empties so slowly, a patient can strictly follow normal fasting rules and still arrive at the operating room with a full stomach.

While this increased risk doesn't prohibit GLP-1 users from going under, it forces medical teams to treat these cases with "full stomach" precautions, modifying their anesthesia plans or altering pre-op prep to actively protect your lungs.

Current Guidance Best Practices

The American Society of Anesthesiologists believes most patients may continue taking their GLP-1s leading up to elective surgery unless their medical teams specifically advise otherwise.

There’s a clinical emphasis on collaborative, patient-tailored approaches: “GLP-1 use … should be based on shared decision-making of the patient with the care team…”

Healthcare staff need to be aware of factors like:

As well as associated conditions which may synergize with the issues GLP-1s present. This can include bowel dysmotility, gastroparesis, or Parkinson’s disease.

When to Pause: Daily vs. Weekly Formulations

Contemporary guidance for GLP-1 cessation before surgery is evolving. In 2023, the ASA took a conservative approach, advising patients on weekly-dosed GLP-1s to skip their last dose a week before surgery, and for daily-dosed GLP-1s to be held on the day of.

Updated multi-society guidance aligns with broader recommendations which prioritize individualized risk factors for aspiration and other complications, rather than dosing frequency alone. Your doctor can assess your personal risk profile and make an informed decision.

However, if your care team determines it is necessary to pause your medication to mitigate aspiration risks, the standard clinical protocol defaults back to how your specific GLP-1 is formulated:

  • Daily Oral Formulations (e.g., daily oral semaglutide or daily liraglutide): Should generally be held on the day of the procedure.
  • Weekly Injectable Formulations (e.g., weekly semaglutide or weekly tirzepatide): Should generally be held for one full week (7 days) before the procedure.

If your team decides it is safest for you to continue your GLP-1 up until surgery, they will often prescribe a 24-hour preoperative liquid diet or perform a point-of-care gastric ultrasound to physically confirm your stomach is empty before administering sedation.

Explore Your Weight Loss Options

Explore Your Weight Loss Options

Explore personalized weight loss treatment options with licensed healthcare providers. If treatment is appropriate, they'll help you choose a plan that fits your health goals and medical needs.

Who May Need Extra Planning

GLP-1s before surgery are generally safe in otherwise healthy or low-risk individuals. That said, you may need to exercise caution before surgery if you fall under specific criteria. These factors may require extra planning on your or your healthcare team’s part.

People Early in Treatment

GLP-1s are titrated. They start at a very conservative dose and over a period of months ramp to what's called a therapeutic dose, or the specific amount of medication that best addresses the target issue while minimizing side effects.

This ramp-up period helps people adjust to the drug but is also when side effects tend to be most prevalent—specifically the gastrointestinal issues that can complicate some surgeries.

If you have surgery scheduled and are still titrating your GLP-1, you should disclose that information to your doctor as early as possible; they may want to delay the surgery until your system stabilizes.

People With Nausea, Vomiting, or Acid Reflux

Gastrointestinal symptoms like nausea, vomiting, or acid reflux can interfere with surgery safety, whether you're on a GLP-1 or not.

Active nausea or reflux indicates that gastric emptying is actively delayed, which severely increases aspiration risks and heavily influences whether your care team will choose to pause the medication.

People Having Procedures With Sedation

GLP-1s aren't known to negatively interfere with medical sedatives—at least not directly. The delayed gastric emptying from GLP-1 can, however, affect the metabolism and efficacy of certain oral sedatives, as well as precipitate an increased risk of aspiration under twilight sedation.

Working around these issues falls mainly on the medical team, not the patient. Healthcare providers may opt to utilize gastrointestinal prokinetics such as metoclopramide to counteract the digestive slowdown and ensure a sedative or anesthetic is effectively distributed throughout the body.

What To Tell Your Medical Team

Your medical team needs comprehensive, accurate information about your health history in order for them to do their jobs effectively. That means disclosing everything. Most of this information will be prompted by medical staff in advance of any procedure. Be prepared to have specifics on:

  • Medication details: Exact brand name, dose, protocol, and date/time of most recent dose.
  • Medication changes: Recent adjustments to dose or delivery mechanism, as well as what stage of titration (if applicable).
  • Current symptoms: Even minor or transient nausea, vomiting, stomach pains, cramping, indigestion, gas, bloating, or reflux.

You should also disclose any other medications you're taking, especially if your healthcare team decides to postpone GLP-1 use to perform surgery.

In short: Tell your healthcare team everything.

Infographic listing what to tell your care team before surgery, colonoscopy, or sedation if you're on a GLP-1.

GLP-1s and Surgery: Questions To Ask

Beyond disclosing your healthcare information, you likely also have questions before surgery. Inpatient and outpatient procedures alike can be stressful. Getting informed reduces anxiety.

Keep these questions front-of-mind:

  • Based on my specific risk profile, should I pause or continue my GLP-1?
  • If we pause, exactly how many days before surgery should I hold my daily or weekly dose?
  • Should I transition to a 24-hour liquid diet prior to the procedure to ensure my stomach is empty?
  • How does my surgery prep interact with a GLP-1 dosing schedule?

Bottom Line

GLP-1s and surgery can safely coexist, but the timing must be handled with care. Because these medications slow down your digestion, standard fasting rules do not always guarantee an empty stomach.

To keep you safe, your care team will evaluate your personal risk profile to decide if you need to pause your medication. If a pause is necessary, the timing depends on your specific formulation. Daily oral doses are typically held on the day of the procedure, while weekly injectables are held a full week out. The right plan depends entirely on your schedule, your symptoms, and how your body responds to the treatment.

The best thing you can do is communicate. Tell your care team about every symptom, even the minor ones, and ask direct questions so you go into your procedure prepared and protected.

Frequently Asked Questions

You don't always have to stop GLP-1s before surgery. The medication can affect certain aspects of the procedure, but whether you have to stop your GLP-1 depends on where you are in your dosing schedule, current symptoms, and the nature of the surgery you're having.

However, if your doctor determines a pause is necessary, daily formulations are typically held the day of surgery, while weekly injectables are held 7 days prior.


Nausea and acid reflux do not necessarily preclude you from being given anesthesia, but active GI symptoms significantly increase the risk of lung aspiration. You must disclose all symptoms to your healthcare team before surgery; they may choose to alter your anesthesia plan, prescribe stomach-emptying medication, or postpone elective surgery for your safety.


Yes, your dentist should be aware of your GLP-1 medication before they sedate you. The gastric delay caused by GLP-1 medications can interfere with the efficacy of certain sedatives and anesthetics and increase the risk of aspiration, even during office-based dental sedation.


Colonoscopy prep may change if you're on a GLP-1. These medications keep food in your stomach longer, which means standard clear-liquid and laxative protocols may not completely clear your system. You may need an extended liquid diet or a temporary pause of your medication in order to achieve the empty bowels required for a successful scan. Ask your doctor for specifics.


You and your healthcare team should make a joint decision about whether to pause GLP-1 medication before surgery. They'll help you weigh the risk factors, current dose, urgency of the procedure, and benefits of stopping the medication or delaying the procedure.

Real Support for Lasting Results

Real Support for Lasting Results

Explore personalized weight loss treatment options with licensed healthcare providers. If treatment is appropriate, they'll help you choose a plan that fits your health goals and medical needs.


  1. Bicket MC, Chua KP, Lagisetty P, Li Y, Waljee JF, Brummett CM, et al. Prevalence of Surgery Among Individuals in the United States. Ann Surg Open. 2024 Apr 11;5(2):e421. doi: 10.1097/AS9.0000000000000421. PMID: 38911632; PMCID: PMC11191855: https://pmc.ncbi.nlm.nih.gov/articles/PMC11191855/
  2. American Society of Anesthesiologists. New multi-society GLP-1 clinical practice guidance released [Internet]. Schaumburg (IL): American Society of Anesthesiologists; 2024 Oct 29 [cited 2026 Jul 19]. Available from: https://www.asahq.org/about-asa/newsroom/news-releases/2024/10/new-multi-society-glp-1-guidance
  3. Jalleh RJ, Marathe CS, Rayner CK, Jones KL, Umapathysivam MM, Wu T, et al. Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024 Nov 26;166(1):bqae155. doi: 10.1210/endocr/bqae155. PMID: 39568409; PMCID: PMC11630531: https://academic.oup.com/endo/article/166/1/bqae155/7906037
  4. Maljaars PW, Peters HP, Mela DJ, Masclee AA. Ileal brake: a sensible food target for appetite control. A review. Physiol Behav. 2008 Oct 20;95(3):271-81. doi: 10.1016/j.physbeh.2008.07.018. Epub 2008 Jul 21. PMID: 18692080: https://pubmed.ncbi.nlm.nih.gov/18692080/
  5. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2025 Jan;39(1):180-183. doi: 10.1007/s00464-024-11263-2. Epub 2024 Oct 29. PMID: 39370500; PMCID: PMC11666732: https://pmc.ncbi.nlm.nih.gov/articles/PMC11666732/
  6. American Society of Anesthesiologists. Patients taking popular medications for diabetes and weight loss should stop before elective surgery, ASA suggests [Internet]. Schaumburg (IL): American Society of Anesthesiologists; 2023 Jun 28 [cited 2026 Jul 19]. Available from: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/patients-taking-popular-medications-for-diabetes-and-weight-loss-should-stop-before-elective-surgery
  7. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022 Jan;24(1):94-105. doi: 10.1111/dom.14551. Epub 2021 Oct 4. PMID: 34514682; PMCID: PMC9293236: https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236/
  8. McKenzie C, DeBernardo A, Schwartz P. Implications of GLP-1 Agonists on Office-Based Sedation and General Anesthesia for Dentistry. Anesth Prog. 2025 Mar 12;72(1):52-58. doi: 10.2344/anpr-72-1-ANPR_Agonists. PMID: 40657828; PMCID: PMC11922517: https://pmc.ncbi.nlm.nih.gov/articles/PMC11922517/
Jake Dickson, NASM-CPT, USAW-L2

By Jake Dickson, NASM-CPT, USAW-L2

Contributing Author

Jake holds a B.S. in Exercise Science from UNC Wilmington and began his career as a personal trainer and weightlifting coach. In recent years, he’s moved behind the page as a writer and editor, contributing hundreds of articles and being featured as a subject matter expert. Today, Jake’s goal remains the same: to empower people to change their lives by bringing heady scientific topics down to ground level.